Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to determine if RPR109881 is a better treatment than
capecitabine (Xeloda) for advanced breast cancer in patients that no longer benefit from
docetaxel and/or paclitaxel.